Emetogenic Risk of
NCCN Levels of Emetogenicity:
Level 5 – High Emetic Risk: 90% frequency of emesis
Chemotherapy and
Level 3/4 – Moderate Emetic Risk: 30‐90% frequency of emesis
Level 2 – Low Emetic Risk: 10‐30% frequency of
emesis
Biotherapy Agents
Level 1 – Minimal Emetic Risk: <10% frequency of emesis
Emetogenicity
Emetogenicity
Agents (alphabetically)
Agents (alphabetically)
AC combo: doxorubicin or epirubicin + cyclophosphamide
5
2
Gemcitabine
Alemtuzumab
1
1
Gemtuzumab ozogamicin
Alpha Interferon < 5000 IU/m2
1
1
Gefitinib (oral)
Amifostine < 300 mg
2
3
Hexamethylmelamine (oral)
Amifostine > 300 ‐ 500 mg/m2
4
1
Hydroxyurea (oral)
Androgens
1
1
Ibritumomab tiuxetan
Arsenic trioxide
3
3
Ifosfamide
Asparaginase
1
1
Imatinib mesylate (oral)
Azacitadine
3
3
Interleukin‐2 > 12‐15 million units/m2
Bendamustine
3
3
Irinotecan
Bevacizumab
1
1
Ixabepilone
Bexarotene (oral)
2
1
Lapatinib (oral)
Bleomycin
1
2
Lenalidomide
Bortezomib
1
3
Lomustine (oral)
Busulfan > 4 mg/d
4
5
Mechlorethamine
Capecitabine (oral)
2
1
Melphalan (oral low‐dose)
Carboplatin
4
4
Melphalan > 50 mg/m2
Carmustine ≤ 250 mg/m2
4
1
Methotrexate ≤ 50 mg/m2
Carmustine > 250 mg/m2
5
2
Methotrexate > 50 mg/m2 < 250 mg/m2
Cetuximab
1
3
Methotrexate 250‐1,000 mg/m2
Chlorambucil (oral)
1
4
Methotrexate > 1,000 mg/m2
Cisplatin ≥50 mg/m2
5
2
Mitomycin
Cisplatin < 50 mg/m2
4
2
Mitoxantrone < 15 mg/m2
Cladribine
1
1
Nelarabine
Clofarabine
3
3
Oxaliplatin > 75 mg/m2
Corticosteroids
1
2
Paclitaxel/Paclitaxel albumin‐bound
Cyclophosphamide (oral)
3
1
Panitumumab
Cyclophosphamide ≤ 750 mg/m2
3
2
Pemetrexed
Cyclophosphamide > 750 mg/m2 to ≤ 1,500 mg/m2
4
1
Pentostatin
Cyclophosphamide > 1,500 mg/m2
5
5
Procarbazine (oral)
Cytarabine (low dose) 100‐200 mg/m2
2
1
Rituximab
Cytarabine > 1 g/m2
4
2
Sorafenib (oral)
Dacarbazine
5
5
Streptozocin
Dactinomycin
4
2
Sunitinib (oral)
Dasatinib (oral)
1
3
Temozolomide (oral)
Daunorubicin
3
1
Temsirolimus
Denileukin diftitox
1
2
Teniposide
Dexrazoxane
1
1
Thioguanine (oral)
Docetaxel
2
2
Topotecan
Doxorubicin (liposomal)
2
1
Tositumomab
Doxorubicin < 60 mg/m2
3
1
Trastuzumab
Doxorubicin >60mg/m2
4
1
Tretinoin (oral)
Epirubicin ≤ 90 mg/m2
3
1
Vinblastine
Epirubicin > 90 mg/m2
4
1
Vincristine
Erlotinib (oral)
1
1
Vinorelbine
Etoposide
2
3
Vinorelbine (oral)
Fluorouracil
2
2
Vorinostat (oral)
Fludarabine
1/2